A detailed history of Bridgefront Capital, LLC transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Bridgefront Capital, LLC holds 21,836 shares of BMY stock, worth $1.26 Million. This represents 0.45% of its overall portfolio holdings.

Number of Shares
21,836
Previous 22,428 2.64%
Holding current value
$1.26 Million
Previous $931,000 21.37%
% of portfolio
0.45%
Previous 0.4%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$39.66 - $51.75 $23,478 - $30,636
-592 Reduced 2.64%
21,836 $1.13 Million
Q2 2024

Aug 14, 2024

BUY
$40.25 - $52.99 $902,727 - $1.19 Million
22,428 New
22,428 $931,000
Q4 2023

Feb 14, 2024

SELL
$48.48 - $57.85 $95,602 - $114,080
-1,972 Reduced 27.44%
5,215 $267,000
Q3 2023

Nov 14, 2023

SELL
$57.89 - $64.73 $795,813 - $889,843
-13,747 Reduced 65.67%
7,187 $417,000
Q2 2023

Aug 14, 2023

BUY
$63.71 - $70.74 $1.33 Million - $1.48 Million
20,934 New
20,934 $1.34 Million
Q4 2022

Feb 14, 2023

BUY
$68.48 - $81.09 $519,694 - $615,392
7,589 New
7,589 $545,000
Q1 2022

May 13, 2022

SELL
$61.48 - $73.72 $282,746 - $339,038
-4,599 Closed
0 $0
Q4 2021

Feb 10, 2022

BUY
$53.63 - $62.52 $246,644 - $287,529
4,599 New
4,599 $287,000
Q3 2021

Nov 12, 2021

SELL
$59.17 - $69.31 $957,725 - $1.12 Million
-16,186 Closed
0 $0
Q2 2021

Aug 12, 2021

BUY
$61.91 - $67.42 $594,521 - $647,434
9,603 Added 145.88%
16,186 $1.08 Million
Q1 2021

May 17, 2021

SELL
$59.34 - $66.74 $409,861 - $460,973
-6,907 Reduced 51.2%
6,583 $416,000
Q4 2020

Feb 12, 2021

BUY
$57.74 - $65.43 $778,912 - $882,650
13,490 New
13,490 $837,000

Others Institutions Holding BMY

About BRISTOL MYERS SQUIBB CO


  • Ticker BMY
  • Exchange NYSE
  • Sector Healthcare
  • Industry Drug Manufacturers—General
  • Shares Outstandng 2,126,160,000
  • Market Cap $123B
  • Description
  • Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...
More about BMY
Track This Portfolio

Track Bridgefront Capital, LLC Portfolio

Follow Bridgefront Capital, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bridgefront Capital, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Bridgefront Capital, LLC with notifications on news.